BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 19804626)

  • 1. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.
    Dupont BF; Lortholary O; Ostrosky-Zeichner L; Stucker F; Yeldandi V
    Crit Care; 2009; 13(5):R159. PubMed ID: 19804626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
    Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
    Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.
    Kuse ER; Chetchotisakd P; da Cunha CA; Ruhnke M; Barrios C; Raghunadharao D; Sekhon JS; Freire A; Ramasubramanian V; Demeyer I; Nucci M; Leelarasamee A; Jacobs F; Decruyenaere J; Pittet D; Ullmann AJ; Ostrosky-Zeichner L; Lortholary O; Koblinger S; Diekmann-Berndt H; Cornely OA;
    Lancet; 2007 May; 369(9572):1519-1527. PubMed ID: 17482982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials.
    Horn DL; Ostrosky-Zeichner L; Morris MI; Ullmann AJ; Wu C; Buell DN; Kovanda LL; Cornely OA
    Eur J Clin Microbiol Infect Dis; 2010 Feb; 29(2):223-9. PubMed ID: 20013016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
    Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
    Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial.
    DiNubile MJ; Lupinacci RJ; Strohmaier KM; Sable CA; Kartsonis NA
    J Crit Care; 2007 Sep; 22(3):237-44. PubMed ID: 17869975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Micafungin in invasive candidiasis among oncohematological patients].
    Jarque I; Angel Sanz M
    Rev Iberoam Micol; 2009 Mar; 26(1):75-7. PubMed ID: 19463282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC).
    Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    Mycoses; 2013 Sep; 56(5):532-42. PubMed ID: 23496163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer.
    Farmakiotis D; Tarrand JJ; Kontoyiannis DP
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3526-9. PubMed ID: 24637687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
    Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
    Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei.
    Shorr AF; Wu C; Kothari S
    J Antimicrob Chemother; 2011 Feb; 66(2):375-80. PubMed ID: 21147825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
    van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
    BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany.
    Cornely OA; Sidhu M; Odeyemi I; van Engen AK; van der Waal JM; Schoeman O
    Curr Med Res Opin; 2008 Jun; 24(6):1743-53. PubMed ID: 18477422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.
    Timsit JF; Azoulay E; Schwebel C; Charles PE; Cornet M; Souweine B; Klouche K; Jaber S; Trouillet JL; Bruneel F; Argaud L; Cousson J; Meziani F; Gruson D; Paris A; Darmon M; Garrouste-Orgeas M; Navellou JC; Foucrier A; Allaouchiche B; Das V; Gangneux JP; Ruckly S; Maubon D; Jullien V; Wolff M;
    JAMA; 2016 Oct; 316(15):1555-1564. PubMed ID: 27706483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease.
    Cornely OA; Marty FM; Stucker F; Pappas PG; Ullmann AJ
    Mycoses; 2011 Nov; 54(6):e838-47. PubMed ID: 21668522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial.
    Timsit JF; Azoulay E; Cornet M; Gangneux JP; Jullien V; VĂ©sin A; Schir E; Wolff M
    Trials; 2013 Nov; 14():399. PubMed ID: 24261608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
    Cross SA; Scott LJ
    Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
    Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of caspofungin and amphotericin B for invasive candidiasis.
    Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J;
    N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.